Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
5.060
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
Next >
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
November 03, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
A Preview Of Editas Medicine's Earnings
November 02, 2023
Via
Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Analyst Ratings for Editas Medicine
October 18, 2023
Via
Benzinga
Is Editas Stock a Buy Now?
October 07, 2023
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?
Via
The Motley Fool
Earnings Scheduled For November 3, 2023
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
Via
Benzinga
Expert Ratings for Editas Medicine
September 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
October 18, 2023
Both are in a race against time to commercialize a medicine before cash runs out.
Via
The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Analyst Expectations for Editas Medicine's Future
August 29, 2023
Via
Benzinga
Expert Ratings for Editas Medicine
August 03, 2023
Via
Benzinga
Is Editas Medicine Stock a Buy Now?
June 28, 2023
The fortunes of this once-promising biotech company have changed in the past year.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 17, 2023
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!
Via
InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
October 17, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
October 05, 2023
It's key to understand the resources it will take to deliver a company's pipeline.
Via
The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
October 02, 2023
The better of the pair should be able to beat Bluebird Bio.
Via
The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
September 29, 2023
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market...
Via
Benzinga
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
1 Gene Editing Stock to Buy Now, and 1 to Sell
September 23, 2023
Target markets matter. So does having the cash to get to them.
Via
The Motley Fool
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
August 23, 2023
Is the Street's optimism justified here?
Via
The Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
June 29, 2023
Reaching profitability could be harder than investors expect.
Via
The Motley Fool
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.